{
    "ticker": "QBIEY",
    "name": "Q Biomed Inc.",
    "description": "Q Biomed Inc. is a biotechnology company focused on commercializing biomedical innovations to improve patient outcomes in a variety of therapeutic areas. Founded in 2015 and headquartered in New York, Q Biomed aims to develop and market unique and effective solutions for unmet medical needs. The company's portfolio includes a range of products at various stages of development, including treatments for serious diseases such as glaucoma, liver cancer, and neurodegenerative disorders. Q Biomed's flagship product, Strontium89, is a radiopharmaceutical for treating metastatic bone pain associated with cancer. Through strategic partnerships and collaborations with research institutions, Q Biomed is committed to advancing its innovative treatments to market, thereby improving the quality of life for patients. The company operates with a focus on ethical practices and strives to ensure that its products are accessible to those in need. With a dedicated management team and a robust pipeline, Q Biomed continues to explore new therapeutic areas and expand its reach in the biotechnology sector.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "New York, New York, USA",
    "founded": "2015",
    "website": "https://www.qbiomed.com",
    "ceo": "David Platt",
    "social_media": {
        "twitter": "https://twitter.com/qbiomed",
        "linkedin": "https://www.linkedin.com/company/qbiomed/"
    },
    "investor_relations": "https://www.qbiomed.com/investors",
    "key_executives": [
        {
            "name": "David Platt",
            "position": "CEO"
        },
        {
            "name": "Michael Redman",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Biopharmaceuticals",
            "products": [
                "Strontium89",
                "QBM-001"
            ]
        },
        {
            "category": "Therapeutics",
            "products": [
                "QBM-101"
            ]
        }
    ],
    "seo": {
        "meta_title": "Q Biomed Inc. | Innovating Biotechnology for Patient Care",
        "meta_description": "Explore Q Biomed Inc., a biotechnology company focused on developing innovative treatments for serious diseases. Discover our product pipeline and commitment to improving patient outcomes.",
        "keywords": [
            "Q Biomed",
            "Biotechnology",
            "Pharmaceuticals",
            "Strontium89",
            "Innovative Treatments"
        ]
    },
    "faq": [
        {
            "question": "What does Q Biomed do?",
            "answer": "Q Biomed is a biotechnology company that develops and commercializes biomedical innovations for various therapeutic areas."
        },
        {
            "question": "Where is Q Biomed headquartered?",
            "answer": "Q Biomed is headquartered in New York, New York, USA."
        },
        {
            "question": "What is Q Biomed's flagship product?",
            "answer": "Q Biomed's flagship product is Strontium89, a radiopharmaceutical for treating metastatic bone pain."
        },
        {
            "question": "When was Q Biomed founded?",
            "answer": "Q Biomed was founded in 2015."
        }
    ],
    "competitors": [
        "AMGN",
        "GILD",
        "REGN"
    ],
    "related_stocks": [
        "JNJ",
        "PFE",
        "MRK",
        "ABBV"
    ]
}